UTHR
United Therapeutics Corporation
Stock
$541.70−29.68 (−5.19%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B | $1.5B | $1.4B | $1.6B | $1.7B | $1.6B | $1.5B | $1.3B | $1.1B | $916M | $743M | $593M | $359M | $281M |
| Cost of revenue | $437M | $384M | $310M | $258M | $152M | $123M | $108M | $118M | $199M | $106M | $73M | $69M | $135M | $141M | $129M | $91M | $69M | $42M | $27M |
| Gross profit | $2.7B | $2.8B | $2.6B | $2.1B | $1.8B | $1.6B | $1.4B | $1.3B | $1.4B | $1.6B | $1.5B | $1.4B | $1.2B | $976M | $787M | $652M | $524M | $317M | $255M |
| R&D | $552M | $550M | $481M | $408M | $323M | $540M | $358M | $1.2B | $358M | $265M | $148M | $245M | $243M | $299M | $173M | $180M | $165M | $120M | $239M |
| SG&A | $764M | $756M | $710M | $477M | $482M | $467M | — | — | $266M | $330M | $317M | $453M | $381M | $394M | $202M | $156M | $189M | $172M | $94M |
| Other operating expenses | — | — | — | — | — | — | $424M | $336M | — | $210M | — | — | — | — | — | — | — | — | $3.1M |
| Operating income | $1.4B | $1.5B | $1.4B | $1.2B | $980M | $556M | $594M | −$188M | $805M | $815M | $1.1B | $699M | $539M | $292M | $422M | $318M | $171M | $26M | −$82M |
| Non-operating income | $171M | $221M | $162M | $89M | −$29M | $38M | $45M | $23M | −$47M | −$45M | −$1.5M | $345M | −$14M | −$14M | $19M | −$19M | −$16M | −$7.1M | — |
| Pretax income | $1.6B | $1.7B | $1.5B | $1.3B | $951M | $594M | $639M | −$165M | $759M | $770M | $1.1B | $1.0B | $525M | $279M | $441M | $299M | $155M | $19M | — |
| Taxes | $262M | $379M | $344M | $290M | $223M | $118M | $124M | −$61M | $170M | $352M | $347M | $393M | $185M | $104M | $136M | $81M | $49M | −$839K | — |
| Net income | $1.3B | $1.3B | $1.2B | $985M | $727M | $476M | $515M | −$105M | $589M | $418M | $714M | $652M | $340M | $175M | $304M | $218M | $106M | $19M | −$49M |
| Diluted EPS | $27.94 | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 | −$2.39 | $13.39 | $9.31 | $15.25 | $12.72 | $6.28 | $3.28 | $5.71 | $3.67 | $1.78 | $0.35 | −$1.08 |
| Diluted shares | — | 47.9M | 48.5M | 49.7M | 48.5M | 47.3M | 44.6M | 43.8M | 44.0M | 44.9M | 46.8M | 51.2M | 54.2M | 53.2M | 53.3M | 59.4M | 59.5M | 56.1M | 45.8M |
| Revenue growth | — | +10.6% | +23.6% | +20.2% | +14.9% | +13.6% | +2.4% | −11.0% | −5.7% | +7.9% | +9.1% | +13.8% | +15.4% | +21.9% | +23.3% | +25.3% | +65.2% | +27.5% | — |
| Gross margin | 86.1% | 87.9% | 89.2% | 88.9% | 92.2% | 92.7% | 92.7% | 91.9% | 87.8% | 93.9% | 95.5% | 95.3% | 89.5% | 87.4% | 85.9% | 87.8% | 88.4% | 88.3% | 90.4% |
| Operating margin | 44.4% | 46.9% | 47.9% | 50.9% | 50.6% | 33.0% | 40.0% | −12.9% | 49.5% | 47.2% | 66.4% | 47.7% | 41.8% | 26.2% | 46.0% | 42.8% | 28.9% | 7.2% | −29.1% |
| Net margin | 41.6% | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | 34.7% | −7.2% | 36.2% | 24.2% | 44.6% | 44.5% | 26.4% | 15.6% | 33.2% | 29.3% | 17.9% | 5.4% | −17.5% |